New Strategies Needed in the Fight against Antimicrobial Resistance

Farah Azouzi*

Farah Azouzi*

Volume4-Issue11
Dates: Received: 2023-11-16 | Accepted: 2023-11-22 | Published: 2023-11-24
Pages: 1611-1613

Abstract

Antimicrobial Resistance (AMR) has become a global threat and has caught high levels. This silent pandemic is challenging healthcare providers as it concerns not only the hospital environment but also community-acquired infections.

FullText HTML FullText PDF DOI: 10.37871/jbres1838

Certificate of Publication

Copyright

How to cite this article

Azouzi F. New Strategies Needed in the Fight against Antimicrobial Resistance. J Biomed Res Environ Sci. 2023 Nov 24; 4(11): 1611-1613. doi: 10.37871/jbres1838, Article ID: JBRES1838, Available at: https://www.jelsciences.com/articles/ jbres1838.pdf

Subject area(s)

Public Health

References

Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19. Erratum in: Lancet. 2022 Oct 1;400(10358):1102. PMID: 35065702; PMCID: PMC8841637.
AMR Review Paper - Tackling a Crisis for the Health and Wealth of Nations.
WAAW-2023-Campaign-guide.
Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, de Waele J, Daikos GL, Akova M, Harbarth S, Pulcini C, Garnacho-Montero J, Seme K, Tumbarello M, Lindemann PC, Gandra S, Yu Y, Bassetti M, Mouton JW, Tacconelli E, Rodríguez-Baño J. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022 Apr;28(4):521-547. doi: 10.1016/j.cmi.2021.11.025. Epub 2021 Dec 16. PMID: 34923128.
Sharma M, Walia K, Bansal N. Unmet needs for management of drug-resistant infections: low- and middle-income countries' viewpoint. Drug Target Insights. 2022 Dec 31;16:78-80. doi: 10.33393/dti.2022.2532. PMID: 36644017; PMCID: PMC9823287.
Njage PMK, van Bunnik B, Munk P, Marques ARP, Aarestrup FM. Association of health, nutrition, and socioeconomic variables with global antimicrobial resistance: a modelling study. Lancet Planet Health. 2023 Nov;7(11):e888-e899. doi: 10.1016/S2542-5196(23)00213-9. PMID: 37940209.
KARPOV SP. Specificheskii bakteriofag v probleme likvidacii briushnogo tifa i briushnykh paratifov [Specific bacteriophage in control of typhoid and paratyphoid]. Zh Mikrobiol Epidemiol Immunobiol. 1946;(1-2):40-4. Undetermined Language. PMID: 20277183.
KNOUF EG, WARD WE, et al. Treatment of typhoid fever with type specific bacteriophage. J Am Med Assoc. 1946 Sep 21;132:134-8. doi: 10.1001/jama.1946.02870380016006. PMID: 20997193.
Perepanova TS, Darbeeva OS, Kotliarova GA, Kondrat'eva EM, Maĭskaia LM, Malysheva VF, Baĭguzina FA, Grishkova NV. Effektivnost' preparatov bakteriofagov pri lechenii vospalitel'nykh urologicheskikh zabolevaniĭ [The efficacy of bacteriophage preparations in treating inflammatory urologic diseases]. Urol Nefrol (Mosk). 1995 Sep-Oct;(5):14-7. Russian. PMID: 8571474.
SOMOVA AG. [On the problem of phage- and antibiotic-therapy of experimental cholrea]. Antibiotiki. 1962 Feb;7:128-35. Russian. PMID: 13915156.
Mboowa G. Reviewing the journey to the clinical application of bacteriophages to treat multi-drug-resistant bacteria. BMC Infect Dis. 2023 Oct 3;23(1):654. doi: 10.1186/s12879-023-08621-1. PMID: 37789281; PMCID: PMC10548642.
Manzanal A, Vicente D, Alonso M, Azkue N, Ercibengoa M, Marimón JM. Impact of the progressive uptake of pneumococcal conjugate vaccines on the epidemiology and antimicrobial resistance of invasive pneumococcal disease in Gipuzkoa, northern Spain, 1998-2022. Front Public Health. 2023 Aug 31;11:1238502. doi: 10.3389/fpubh.2023.1238502. PMID: 37719737; PMCID: PMC10501722.
Unemo M, Lahra MM, Escher M, Eremin S, Cole MJ, Galarza P, Ndowa F, Martin I, Dillon JR, Galas M, Ramon-Pardo P, Weinstock H, Wi T. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017-18: a retrospective observational study. Lancet Microbe. 2021 Nov;2(11):e627-e636. doi: 10.1016/S2666-5247(21)00171-3. Epub 2021 Sep 2. PMID: 35544082.
Johnson B. GSK's gonorrhea vaccine receives fast-track designation to expedite clinical trials. Nat Med. 2023 Sep;29(9):2146-2147. doi: 10.1038/d41591-023-00069-9. PMID: 37550402.
Wantuch PL, Rosen DA. Klebsiella pneumoniae: adaptive immune landscapes and vaccine horizons. Trends Immunol. 2023 Oct;44(10):826-844. doi: 10.1016/j.it.2023.08.005. Epub 2023 Sep 11. PMID: 37704549.
Wang Z, Guo G, Li Q, Li P, Li M, Zhou L, Tan Z, Zhang W. Combing Immunoinformatics with Pangenome Analysis To Design a Multiepitope Subunit Vaccine against Klebsiella pneumoniae K1, K2, K47, and K64. Microbiol Spectr. 2022 Aug 31;10(4):e0114822. doi: 10.1128/spectrum.01148-22. Epub 2022 Jul 12. PMID: 35863000; PMCID: PMC9431259.
Ranjbarian P, Sobhi Amjad Z, Chegene Lorestani R, Shojaeian A, Rostamian M. Klebsiella pneumoniae vaccine studies in animal models. Biologicals. 2023 May;82:101678. doi: 10.1016/j.biologicals.2023.101678. Epub 2023 Apr 29. PMID: 37126906.
Tan YC, Lahiri C. Promising Acinetobacter baumannii Vaccine Candidates and Drug Targets in Recent Years. Front Immunol. 2022 May 26;13:900509. doi: 10.3389/fimmu.2022.900509. PMID: 35720310; PMCID: PMC9204607.
LimmaTech Biologics AG. Safety and Immunogenicity of a Klebsiella pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A FTIH Phase I/II Randomized and Controlled Study. ClinicalTrials.gov. 2022.
Mendes SG, Combo SI, Allain T, Domingues S, Buret AG, Da Silva GJ. Co-regulation of biofilm formation and antimicrobial resistance in Acinetobacter baumannii: from mechanisms to therapeutic strategies. Eur J Clin Microbiol Infect Dis. 2023 Dec;42(12):1405-1423. doi: 10.1007/s10096-023-04677-8. Epub 2023 Oct 28. PMID: 37897520; PMCID: PMC10651561.